cancerfacts.com - log on. fight back. Patients and Caregivers
Healthcare Professionals
 
General Services
  Cancer News
  Links and Resources
Help Center
  Help
  Contact Us
  Suggestion Box
About Us
  About cancerfacts.com
  In the News
  User Comments







Aspirin may increase prostate cancer survival
Source: (cancerfacts.com)
Monday, October 04, 2004


ATLANTA – Oct. 4, 2004 – Men with prostate cancer might survive longer by regularly taking aspirin, a new study suggests.

While there have been other studies showing regular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) seems to reduce the risk of developing various cancers, including prostate cancer, this is one of the first to suggest that such drugs may help men with prostate cancer live longer.

The study led by Dr. K Khanh H. Nguyen, a radiation oncologist at Fox Chase Cancer Center was presented today at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO).

"Pretreatment NSAID use was associated with significant delays in distant metastases, decreased rates of second cancers and improvement in overall survival," lead author Nguyen said in a news release. "Our data suggest a potential benefit of NSAIDs in managing prostate cancer."

The Fox Chase study involved 1,206 men who had definitive radiation therapy for localized prostate cancer. The researchers compared long-term treatment outcomes of 232 patients who had used NSAIDs regularly before treatment with the outcomes of the 974 men with no history of regular NSAID use. Other characteristics, such as smoking, were balanced between the two groups. The follow-up period averaged more than four and a half years.

After taking into account other variables such as age, Gleason score and radiation dose, the use of anti-inflammatory drugs remained a predictor for improved overall survival.

Laboratory studies have suggested that by inhibiting the COX-1 and COX-2 enzymes, NSAIDs may enhance programmed cell death (apoptosis) and inhibit the development of blood vessels (angiogenesis) that feed a tumor. The Fox Chase researchers concluded that inhibiting these COX enzymes holds promise in prostate cancer treatment and warrants further studies.

Copyright © 2001, 2002, 2003, 2004 NexCura, Inc. All rights reserved. Republication or redistribution of cancerfacts.com content, including by framing or similar means, is expressly prohibited without the prior written consent of NexCura. NexCura® is a registered trademark and cancerfacts.com™ is a trademark of NexCura, Inc. or its affiliates. Copyright © 2001, 2002, 2003, 2004. All rights reserved. This information is for educational purposes only.








Top


Powered By Nexcura

   Terms and Conditions
   Privacy Statement
   Trademark and Copyright


  search by keyword




GO

Advanced Search


Long-term aspirin use may increase risk of pancreatic cancer

Aspirin may boost cancer therapy

An aspirin a day may help keep prostate cancer away






Bladder
Breast
Cervical
Colorectal
Head and Neck
Hodgkin Lymphoma
Kidney
Leukemia - Adult ALL
Leukemia - Adult AML
Leukemia - Adult CML
Lung - Non-Small Cell
Lung - Small Cell
Melanoma
Multiple Myeloma
Non-Hodgkin's Lymphoma
Ovarian
Pancreatic
Prostate
Testicular
Uterine



HON Logo
We subscribe to the
HONcode principles
of the
Health On the Net
Foundation






HOME | CONTACT US | SUGGESTION BOX | SITE MAP


cancerfacts.com, the cancerfacts.com logo, NexCura, Heart Profiler, the NexCura logo, the Heart Profiler logo and the Powered by NexCura logo are either trademarks or registered trademarks of NexCura, Inc. Copyright © NexCura, Inc. All rights reserved. U.S. Patent No. 6,581,038 & Patents Pending. Other foreign patents may apply.
This information is for educational purposes only. cancerfacts.com does not host advertising in any form.